Study on Use of Avelumab in Combination with Crizotinib or Lorlatinib in Patients with NSCLC
Study on Use of Avelumab in Combination with Crizotinib or Lorlatinib in Patients with NSCLC. A Phase 1b/2, Open-Label, Dose Finding Study to Evaluate Safety, Efficacy, Pharmacokinetics and Pharmacodynamics of Avelumab (MSB0010718C) in Combination With Either Crizotinib or PF-06463922 in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer.
Category & Conditions: Cancer
Medicine: Bavencio (avelumab)
Lorbrena (lorlatinib)
XALKORI®(CRIZOTINIB)
ClinicalTrials.gov Identifier (NCT): NCT02584634
Protocol ID: B9991005
PrintDownloadOpen Plain Language Summary Result: Click here